Overview

  • Product name
    Pemirolast potassium
  • Description
    Mast cell stabilizer. Antiallergic agent.
  • Alternative names
    • 9-Methyl-3-(2H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one potassium salt
    • Alamast
    • Alegysal
    • BMY 26517
    • TBX
    see all
  • Biological description

    Mast cell stabilizer that acts as an antiallergic agent. Inhibits chemical mediator release from tissue mast cells. Inhibits the release of sensory nerve peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP). Used for the treatment of allergic conjunctivitis.

  • Purity
    > 99%

Properties

  • Chemical name
    9-Methyl-3-(2H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one potassium salt
  • Molecular weight
    266.30
  • Chemical structure
    Chemical Structure
  • Molecular formula
    C10H7KN6O
  • CAS Number
    100299-08-9
  • Storage instructions
    Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview
    Soluble in water to 100 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • Source

    Synthetic

References

This product has been referenced in:
  • Itoh Y  et al. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology 46:888-94 (2004). Read more (PubMed: 15033348) »
  • Abelson MB  et al. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther 18:475-88 (2002). Read more (PubMed: 12419098) »
  • Ohsawa H  et al. Preventive effects of an antiallergic drug, pemirolast potassium, on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 136:1081-7 (1998). Read more (PubMed: 9842024) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab145718.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up